Korkmaz, P. And Demirtürk, N. 2024. Discontinuation of Nucleos(t)ide Analogues in HBeAg Negative Chronic Hepatitis B Patients: Risks and Benefits. IDCM , vol.6, no.2 , 70-77.

Korkmaz, P., & Demirtürk, N., (2024). Discontinuation of Nucleos(t)ide Analogues in HBeAg Negative Chronic Hepatitis B Patients: Risks and Benefits. IDCM , vol.6, no.2, 70-77.

Korkmaz, PINAR, And Neşe Demirtürk. "Discontinuation of Nucleos(t)ide Analogues in HBeAg Negative Chronic Hepatitis B Patients: Risks and Benefits," IDCM , vol.6, no.2, 70-77, 2024

Korkmaz, PINAR And Demirtürk, Neşe. "Discontinuation of Nucleos(t)ide Analogues in HBeAg Negative Chronic Hepatitis B Patients: Risks and Benefits." IDCM , vol.6, no.2, pp.70-77, 2024

Korkmaz, P. And Demirtürk, N. (2024) . "Discontinuation of Nucleos(t)ide Analogues in HBeAg Negative Chronic Hepatitis B Patients: Risks and Benefits." IDCM , vol.6, no.2, pp.70-77.

@article{article, author={PINAR KORKMAZ And author={Neşe Demirtürk}, title={Discontinuation of Nucleos(t)ide Analogues in HBeAg Negative Chronic Hepatitis B Patients: Risks and Benefits}, journal={IDCM}, year=2024, pages={70-77} }